增殖性糖尿病视网膜病变患者房水、玻璃体与血浆细胞因子水平的相关性
该研究纳入17例增殖性糖尿病视网膜病变(PDR)患者和7例对照,用多重免疫分析检测玻璃体、房水和血浆中10种细胞因子,发现玻璃体与房水中IL-8、PlGF和VEGF-A显著相关,而血浆细胞因子与眼内无相关性;近期抗VEGF注射降低房水VEGF-A水平,但不影响其他细胞因子。
要点
- PDR患者玻璃体和房水中IL-8、PlGF、VEGF-A显著相关,房水或可替代玻璃体检测部分细胞因子。
- 血浆细胞因子与玻璃体、房水细胞因子均无显著相关性。
- 近期抗VEGF注射降低房水VEGF-A水平,但其他细胞因子不受显著影响。
核心结论
- 在PDR患者中,IL-8、VEGF-A和PlGF在玻璃体与房水之间呈强相关,房水可能作为某些PDR相关细胞因子的玻璃体替代检测样本。
- 近期抗VEGF注射降低房水VEGF-A水平,但未显著影响其他细胞因子,提示其他靶向治疗可能在PDR管理中发挥作用。
研究设计与样本
- 研究纳入17例PDR患者和7例对照,采集玻璃体、房水和血浆样本,用多重免疫分析检测10种PDR相关细胞因子。
- 主要结局为玻璃体、房水和血浆中细胞因子的相关性,次要结局为对照与伴或不伴近期抗VEGF注射的糖尿病患者之间细胞因子水平的比较。
主要发现
- 与对照相比,糖尿病患者玻璃体中IL-6、IL-8、TNF-α、MCP-1、MIP-1β、PlGF和VEGF-A升高,房水中IL-6、IL-8、PlGF和VEGF-C升高(均P < 0.05)。
- PDR患者玻璃体与房水中IL-8、PlGF和VEGF-A显著相关(均P < 0.05)。
- 血浆细胞因子与玻璃体和房水细胞因子均无相关性(均P > 0.05)。
- 玻璃体和房水中IL-6、IL-8、TNF-α、PlGF和VEGF-A在对照与伴或不伴近期抗VEGF注射的糖尿病患者间存在差异(均P < 0.05)。
- 一对一比较中,近期接受抗VEGF注射的糖尿病患者房水VEGF-A水平低于未接受者(P = 0.01)。
关键数值与推荐
- PDR患者玻璃体与房水中IL-8、PlGF和VEGF-A显著相关(均P < 0.05)。
- 血浆细胞因子与玻璃体和房水细胞因子均无相关性(均P > 0.05)。
- 近期抗VEGF注射者房水VEGF-A水平低于未注射者(P = 0.01)。
临床怎么用
- 房水检测IL-8、PlGF和VEGF-A或可反映玻璃体水平,为PDR的微创监测提供参考。
- 血浆细胞因子不能替代眼内细胞因子检测,临床评估PDR炎症状态应优先考虑眼内样本。
- 抗VEGF治疗后房水VEGF-A下降而其他细胞因子不受显著影响,提示联合其他靶向治疗可能有必要。
局限性
- 本研究为概念验证性研究,样本量较小(17例PDR患者和7例对照)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the relationship between proangiogenic and inflammatory cytokines in concurrent vitreous, aqueous, and plasma samples from patients with proliferative diabetic retinopathy (PDR). METHODS: Vitreous, aqueous, and plasma samples were analyzed using multiplex immunoassay for 10 PDR-related cytokines (IL-6, IL-8, TNF-α, monocyte chemoattractant protein-1 [MCP-1], macrophage inflammatory protein-1β [MIP-1β], VEGF receptor 1 [Flt-1], placental growth factor [PlGF], VEGF-A, VEGF-C, VEGF-D). A total of 17 patients with PDR and 7 controls were included. The primary outcome was correlation of cytokines in vitreous, aqueous, and plasma. The secondary outcome was the comparison of cytokine levels in controls and diabetics with and without recent anti-VEGF injection. RESULTS: The following factors were elevated in diabetics compared with controls: vitreous IL-6, IL-8, TNF-α, MCP-1, MIP-1β, PlGF, and VEGF-A; and aqueous IL-6, IL-8, PlGF, and VEGF-C (all P < 0.05). Vitreous and aqueous IL-8, PlGF, and VEGF-A were significantly correlated in patients with PDR (all P < 0.05). Plasma cytokines were not correlated with those in vitreous and aqueous (all P > 0.05). Vitreous and aqueous IL-6, IL-8, TNF-α, PlGF, and VEGF-A differed among controls and diabetics with and without recent anti-VEGF injection (all P < 0.05). In one-to-one comparisons, aqueous VEGF-A levels were lower in diabetic patients who had recent anti-VEGF injection compared with those who did not (P = 0.01). CONCLUSIONS: In this proof-of-concept study, IL-8, VEGF-A, and PlGF demonstrated a strong correlation in vitreous and aqueous of patients with PDR. The aqueous may serve as a proxy for vitreous for some cytokines involved in PDR. Recent anti-VEGF injections decreased VEGF-A levels in aqueous, but did not significantly affect other cytokines, suggesting a role for other targeted therapies in PDR management.
引用
- Wu F, Phone A, Lamy R, et al. Correlation of Aqueous, Vitreous, and Plasma Cytokine Levels in Patients With Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2020. PMID: 32084272. doi:10.1167/iovs.61.2.26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。